Photon (Photon Health), a developer of the end-to-end AI-powered digital prescription infrastructure for modern healthcare, raised $16 million in a Series A round.
Healthier Capital led the investment round with participation from Notation, Flare Capital, and Evidenced.
With fresh funds, Photon Health will expand the engineering and commercial teams, drive expanded health system and platform integrations, and accelerate adoption of its modern prescribing and medication access tools.
Photon is rebuilding the prescription experience from the ground up, not as a pricing widget or a single-point fix, but as a full end-to-end platform.
That means: Modern prescribing and routing infrastructure; a network of pharmacy partners across retail and home delivery; a consumer-facing marketplace that surfaces real-time price and stock information; and a full suite of capabilities, including prior authorization, clinical decision support, and beyond.
“We’re building prescription infrastructure for the AI era. We’re scaling at a critical juncture where healthcare SaaS and services are being disrupted by LLMs and agentic workflows — right as healthcare affordability and consumer demand for transparency reach a boiling point. We’re leveraging this technology to empower consumers, enable true price transparency, and push the pharmacy industry back toward an open marketplace,” said Otto Sipe, Photon founder and CEO.
Digital health companies, including AI-powered digital prescription startups, have secured more than $180 billion in funding to date, according to our recent 2026 Funding Database.
The funding activity is mainly driven by AI-driven digital health startups in 2026. Notable recent funding rounds include:
- Aidoc, a global leader in enterprise-scale clinical AI focused on helping physicians make earlier, safer diagnoses by turning raw patient signals into actionable insight, raised $150 million in a Series E funding round.
- Iterative Health, an AI-powered healthcare technology and services company powering the acceleration of clinical research, raised $77 million in a Series C financing round.